
Александру Гаснаш
According to the minister, the new system will enable the authorities to compare the effectiveness and costs of different treatments, negotiate more favourable prices and make more efficient use of the health budget.
“Firstly, treatments will be assessed based on the actual benefit to the patient, not simply on how new or how expensive they are. If there are two medicines with similar effectiveness for the same condition, but one costs three times as much, there is no justification for paying the extra cost. Secondly, we will negotiate better prices, and with the money saved we will be able to treat more people,” said Alexandru Gașnaș.
The minister specified that funding decisions will be based on clear and publicly available criteria. The authorities will use the assessments carried out by European agencies, adapting them to budgetary constraints and the needs of patients in the Republic of Moldova.
“Implementation will begin gradually, from 1 January 2027, starting with medicines. This does not mean that every new medicine will be automatically funded, but that we will be able to identify treatments that offer proven benefits and for which it is worth using public money,” explained the minister.
The National Health Technology Assessment (HTA) mechanism was approved by the Government on 21 October 2026. It introduces, for the first time in the Republic of Moldova, a common system for assessing medicines, medical devices and other health technologies prior to their inclusion in or continued coverage under public funding. Implementation will take place in stages: from 1 January 2027, the mechanism will apply to medicines; from 2028, it will be extended to medical devices and other technologies; and from 2029, it will become the sole means of admitting and retaining them in the public funding scheme. Medicines and technologies already funded will retain their funding under the current conditions until they are reassessed.
This story was translated with the assistance of artificial intelligence.
Follow our updates
Have information for the newsroom? Share it with Logos-Press



























Comments
0No comments yet. You can start the conversation.
Comments are open to readers with a Logos Press account.
Sign in to comment